


Roche: Defining priorities for a high tech healthcare company

*Erich Hunziker, Deputy Head of the
Corporate Executive Committee and CFO
January 2008*



This presentation contains certain forward-looking statements. These forward-looking statements may be identified by words such as 'believes', 'expects', 'anticipates', 'projects', 'intends', 'should', 'seeks', 'estimates', 'future' or similar expressions or by discussion of, among other things, strategy, goals, plans or intentions. Various factors may cause actual results to differ materially in the future from those reflected in forward-looking statements contained in this presentation, among others:

- 1 pricing and product initiatives of competitors;
- 2 legislative and regulatory developments and economic conditions;
- 3 delay or inability in obtaining regulatory approvals or bringing products to market;
- 4 fluctuations in currency exchange rates and general financial market conditions;
- 5 uncertainties in the discovery, development or marketing of new products or new uses of existing products, including without limitation negative results of clinical trials or research projects, unexpected side-effects of pipeline or marketed products;
- 6 increased government pricing pressures;
- 7 interruptions in production
- 8 loss of or inability to obtain adequate protection for intellectual property rights;
- 9 litigation;
- 10 loss of key executives or other employees; and
- 11 adverse publicity and news coverage.

Any statements regarding earnings per share growth is not a profit forecast and should not be interpreted to mean that Roche's earnings or earnings per share for this year or any subsequent period will necessarily match or exceed the historical published earnings or earnings per share of Roche.

For marketed products discussed in this presentation, please see full prescribing information on our website - www.roche.com

All mentioned trademarks are legally protected



Additional information in relation to the offer for Ventana shares and where to find it

These materials are for informational purposes only and do not constitute an offer to purchase or a solicitation of an offer to sell Ventana's common stock. The tender offer is being made pursuant to a tender offer statement on schedule TO (including the offer to purchase, letter of transmittal and other related tender offer materials) filed by Roche with the Securities and Exchange Commission (SEC) on June 27, 2007. These materials, as they may be amended from time to time, contain important information, including the terms and conditions of the offer, that should be read carefully before any decision is made with respect to the tender offer. Investors and stockholders can obtain a free copy of these materials and other documents filed by Roche with the SEC at the website maintained by the SEC at www.sec.gov. The tender offer materials may also be obtained for free by contacting the information agent for the tender offer, Mackenzie Partners, at (212) 929-5500 or (800) 322-2885 (toll-free). Additional information can also be found on www.roche.com.

3



Performance up-date

Our priorities

4

Continuing excellent growth

Over CHF 3.5 billion organic sales added




CHF bn	2006	2007	% change in		USD growth
	YTD Sept	YTD Sept	CHF	local	
Pharmaceuticals	23.9	27.1	13	14	17
Diagnostics	6.4	6.8	6	5	10
Roche Group	30.3	33.9	12	12	16

5


Oncology: Annualised sales of over CHF 18 billion

... and growing strongly



6

Strong rise in Group sales and Core EPS



Historical Core EPS data 2003 to 2004 restated

7

Strategic acquisitions and portfolio enhancements



Committed to technology leadership

Driving personalised healthcare

Leader in Pharma

Leader in Diagnostics

- **THP** (therapeutic antibody technology)
- **Alnylam** (RNA interference technology)
- **Transgene** (therapeutic HPV vaccine)
- **BioVeris** (electrochemiluminescence technology)
- **454 Life Sciences** (ultra fast gene sequencing)
- **NimbleGen** (high-density DNA microarrays)
- **Ventana** (tissue-based diagnostics)¹
- **Tanox** (acquired by Genentech)



¹ Tender offer pending

8

Growth objectives for 2007

Reconfirming improved outlook of Q1

Sales

- Double-digit sales growth¹ for Roche Group and Pharmaceuticals Division
- Above-market sales growth in both divisions

Core EPS target

- Core earnings per share growth above sales growth

¹ in local currencies

barring unforeseen events

9


Performance up-date

Our priorities

10

Roche Challenge # 1

Achieve above peer level sales growth for both divisions




11

YTD Sept '07: Sales growth two-to-three times market


Growing share of key growth drivers



Local sales growth



Key products as % of pharma sales




12

Key products on growth path


New indications provide fresh growth opportunities




Avastin




Herceptin



Tarceva



MabThera



■ Pharma Division sales
■ Roche Pharma sales

MAT = Rolling 4 quarter sales at avg. YTD Sept. '07 exchange rates

13

Our oncology strategy: Setting new standards of care

New tumor types, new combinations, new lines of intervention



Clinically differentiated product


target all tumor types

target all possible combinations

target earlier (adjuvant) intervention

Superior outcome for patients

Example Avastin



14

Oncology



Many market opportunities on the horizon and addressed

	CRC	NSCLC	BC HER2+	BC HER2-	RCC
Adjuvant	Approval	Xeloda (mono)		Herceptin	
	Trials	P3 Avastin, Xeloda (combo)	P3 Avastin; Tarceva	P3 Herceptin+ Avastin (in planning)	P3 Avastin; Xeloda
Metastatic 1st line	Approval	Avastin, Xeloda (mono)	Avastin	Herceptin, Avastin (EU)	Avastin (EU), Xeloda
	Trials	Filed Avastin (EU), Xeloda (EU,US) line ext with oxaliplatin	P3 Avastin+ Tarceva, Tarceva maint.	P3 Herceptin+ Avastin; Herceptin+ pertuzumab	P3 Avastin line ext.
Metastatic 2nd line	Approval	Avastin (US)+ filed (EU)	Tarceva	Herceptin Xeloda	Xeloda
	Trials		P3 Tarceva+ Avastin		P3 Avastin

Approved
 Filed
 New market opportunities addressed

15


Funding



Roche oncology products are cost-effective

Cost per QALY for selected drugs (UK data – NICE/SMC)


GBP in (000)



16


Oncology is still dramatically under funded

Compared to other disease areas



Roche has a low exposure to generics

Long-term sustainable business



Roche has a unique „investment case“



Roche: Unique geographic risk diversification

USA

(Greater)
Europe

Japan

Asia China

Latin
America

Roche: Unique “pillars of value” risk diversification

Avastin
in CRC

Avastin
in NSCL

Avastin
in BC

MabThera

Xeloda

Herceptin

Tarceva

Actemra

MabThera in RA

Pegasys

Neo Recormon

Mircera

Diabetes Care

Immuno-
Diagnostics

Boniva

CellCept

Molecular
Diagnostics

Avastin adjuvant
CRC

Avastin adjuvant
NSCLC

Avastin adjuvant
in BC

CETP i

GLP - 1

Pertuzumab

Ocrelizumab (AD)

FUTURE PILLARS

19

The short/medium term *sales* perspective



Challenge # 1:

Achieve above industry-standard sales growth

Conclusion # 1:


Roche wants to maximize assets on hand –
and to translate value opportunities into reality



20

Challenge # 2

Turn attractive top line into attractive bottom line



21

Doing the right things *right*

Three focus areas



- **People are key!**

Activate potential and constantly educate: to learn faster than our competitors is the only sustainable factor of success!

- **The right “quantum” size for Roche ?**

Fixed cost versus variable cost

- **Operational productivity**

22

Activate our employees' potential

Constant education to overcome fear of change




23

What is the right quantum size for a “sustainable” Roche?



Even if costs grow considerably slower than sales”, there is risk that we build up too much infrastructure / fixed costs!




24

Constantly improving operational productivity



Operational productivity is an important key enabler for the Roche Group



We must become better and cheaper in whatever we do!


25

Focus on differentiated products paying off


Sales doubling, operating profits tripling



Group sales¹ (CHF bn)



Group operating profit² (CHF bn)



¹ Pharmaceuticals and Diagnostics


² before exceptional items

26

Core EPS rising steadily



Core EPS CAGR¹ ('02 - '06): 23 %



¹ Compound Annual Growth Rate


27

Economic success translated into shareholder returns



Again a substantial increase in 2006

Dividend CAGR¹ ('91-'06): 18 %



¹ Compound Annual Growth Rate

1995 including centenary bonus

2006 Dividend: Proposed by the Board of Directors

28

Short/medium term *bottom-line* perspective



Challenge # 2:


Achieve above industry-standard value creation

Conclusion # 2:

Roche has many programs running to ensure above industry standard EPS-growth

29


Challenge # 3 *Filling the "strategic gap"*



30

Sustainable leadership

How can we constantly provide benefit to customers?




Which degree of innovation (= medical differentiation) is necessary to jump regulatory and reimbursement hurdles?

31

Innovation and Change Management


Performance improvements are not linear



32

Large-Scale Transformation

Requires multiple S-Curves building on each other




- Critical for large scale transformation is that major innovations build on each other
- Combination of quantum-leap progress and continuous improvement
 - Organisation needs a major step change every few years followed by a period of stability to digest, optimize and continuous improvements

33

The Roche “hub & spoke”-model:

Roche controls the global value chain, but is open for Research partnerships




34

Access to Innovation is key - competition growing

Costs of third party innovation is raising steeply!

Average cost of in-licensing (Rx), \$m




- Average cost of in-licensing deals rose 40% (CAGR) since 2000
- By 2010, 40% of Pharma peers' revenues expected to come from external sources of innovation

Roche 2015: Disease Biology Areas (DBAs)

Alignment and focus



Disease Biology Areas


Idea ← → Market




- Focus on five DBAs
- Decisions made by Disease Biology Leadership Teams (DBLTs) against measurable metrics
- **Up to Proof of Concept:** DBLTs manage compound progression within respective DBA
- **After Proof of Concept:** DBLTs responsible for conducting scientific/ medical reviews and providing options to Pharma Leadership Team

- Clear focus
- More independent and flexible disease areas
- Faster and simpler decision processes







YTD Sep 2007 Metabolism/Diabetes pipeline making good progress- major new area for Roche emerging

CETP Inhibitor

- Phase IIb data available internally: very encouraging
- Torcetrapib side effects (elevated blood pressure) appear compound-specific

GLP-1 phase II data available soon

- First phase II data (sustained release formulation) before year end
- Decision for phase III to be taken in early 2008

DDP-IV (3) moves into phase II

- Good safety profile
- Potential for weight reduction?

40

Long-term perspective
Roche 2015 is a crucial platform



Challenge # 3:
Filling the value gap



Conclusion 3:
With Roche 2015 we have the right platform in place
to identify the right priorities

41



We Innovate Healthcare